Trial Profile

A Phase 2a clinical trial assessing TRX01 in people with moderate to severe COVID19

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Travatrelvir (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

15 May 2025 According to Traws Pharma media release, preparations are underway for regulatory briefings and Phase 2 studies.
26 Mar 2025 According to Traws Pharma media release, preparations are underway to meet with the FDA to align on a path forward and initiate Phase 2 study.
30 Sep 2024 According to Traws Pharma media release, Based on the Phase 1 data, company have selected the dose for this Phase 2a study, expected to begin in H1 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com